[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nova Scotia Health Authority\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":688},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,70,0,25,[9,48,83,111,141,169,194,223,247,275,307,331,354,379,406,430,457,491,518,543,569,594,619,639,661],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644907","impact-of-communication-delays-on-anesthesia-response-to-medical-emergencies-and-ultrasound-guided-regional-anesthesia-100644907",false,"NCT07675863","Impact of Communication Delays on Anesthesia Response to Medical Emergencies and Ultrasound-Guided Regional Anesthesia","The Impact of Communication Delays on Anesthesia Response to Medical Emergencies and Ultrasound-Guided Regional Anesthesia: A Randomized Simulation Study","ICARUS","Inclusion Criteria:\n\n* Medical students from Dalhousie University and Canadian Armed Forces (CAF) medical technicians or nurses at a minimum of Rank Qualification Medical Technician Private\n\nExclusion Criteria:\n\n* prior experience and training in regional anesthesia techniques\n* visual\u002Fauditory impairments that make unmodified video chats difficult",true,"ALL",{"count":21,"type":22},42,"ESTIMATED","INTERVENTIONAL",[25],"NA","Hypotheses The investigators hypothesize that a communication delay of 80 seconds compared to no delay will be associated with longer procedural times and decreased quality during brachial plexus block scanning. Secondly, the communication delay will be associated with more errors in treatment and a delay of essential treatments in a medical emergency.\n\nBackground The near future will see crewed missions in deep space. As the number of people travelling to space increases, so will the chances of traumatic injury and other medical emergencies. Given many changes to body systems in microgravity and the scarcity of equipment and personnel in space, treating medical emergencies is already very difficult. Because most pain medications interfere with cognition, and general anesthesia would be very risky in these conditions, regional anesthesia ('nerve blocks') has been suggested as a less risky alternative. However, nerve blocks are highly specialized skills and responding to medical emergencies in general requires extensive medical training, it is likely that astronauts will require guidance from earth-based physicians.\n\nAs crews venture deeper into space, the ability of teams to communicate in real time with earth-based medical teams decreases. For missions to the moon, communication delays of 3 to 160 seconds in each direction are expected. In the event of a medical emergency, space crews may require consultation with ground teams. The investigators predict that this communication delay will impact task duration, create opportunities for miscommunication and potentially result in higher rates of complications.\n\nObjectives\n\n* Quantify the difference (communication delay versus no delay) in time to identify critical structures while scanning brachial plexus block sonoanatomy and time to essential treatment during a medical emergency.\n* Quantify the difference (communication delay versus no delay) in quality and ease of imaging while scanning brachial plexus block sonoanatomy.\n* Quantify the difference in completeness of emergency treatment using a composite measure (communication delay versus no delay).\n* Describe the challenges and solutions for team functioning and remote mentorship when a communication delay exists.\n\nMethods This is a within-subjects, mixed-methods, simulation-based randomized study. Regional anesthesia novices (medical students) and Canadian Armed Forces (CAF) medical technicians or CAF nurses will be recruited and given a 4-hour training session on the basics of brachial plexus blocks and their complications. Participants will be placed in teams of 3, participating in two simulation scenarios. Once the team enters the simulation space, they will be able to ask for assistance from a \"remote\" team of experts. Teams will be guided through identifying the sonoanatomy for brachial plexus blocks and responding to a complication from placing a peripheral nerve block. Every team will complete both the no communication delay and 80-second communication delay. Teams will be randomly assigned the order in which they perform each condition.\n\nTime to \"block\" (when the participant identifies where they would place the local anesthetic) and time to essential treatments during an emergency will be recorded. Participants will rate the ease of ultrasound image acquisition and ease of communication, while the expert team will rate the quality of the ultrasound images and the ease of communication. Quantitative outcomes will be analyzed using univariate statistics. After the scenario, teams will debrief the scenario with a focus on communication, safe identification of target nerves and their ability to respond to a complication. Transcriptions of the debriefing sessions will be analyzed for themes using qualitative analysis.",[28,29,30,31],"Regional Anesthesia","Regional Anesthesia Morbidity","Regional Anesthesia Success","Remote Consultation, Teleconsultation",[33,34],"Communication delay","Space Medicine","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":22},"2026-07-11",{"date":43,"type":22},"2027-04-15",{"name":45,"class":46},"Nova Scotia Health Authority","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100440593","phase-4-optimized-predictive-treatment-in-medications-for-unipolar-major-depression-optimum-d-100440593","NCT05017311","Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)","CAN-BIND-17","Patients\n\nInclusion Criteria:\n\n* Outpatients 18 to 65 years of age.\n* Meet DSM-5 criteria for MDE in MDD as determined by SCID-5.\n* Free of psychotropic medications for at least 5 half-lives (e.g. 1 week for most antidepressants, 5 weeks for fluoxetine) before baseline Visit 1 (exceptions: stable use of hypnotics; stable use of stimulants for attention-deficit\u002Fhyperactive disorder).\n* MADRS score ≥ 24.\n* Fluency in English, sufficient to complete the interviews and self-report questionnaires.\n\nExclusion Criteria:\n\n* Any diagnosis, other than MDD, that is considered the primary diagnosis.\n* Bipolar I or Bipolar-II diagnosis.\n* Presence of a significant Axis II diagnosis (borderline, antisocial).\n* High suicidal risk, defined by clinician judgment.\n* Substance dependence\u002Fabuse in the past 6 months.\n* Presence of significant neurological disorders, head trauma, or other unstable medical conditions.\n* Pregnant or breastfeeding.\n* Failure of 4 or more adequate pharmacologic interventions (as determined by the Antidepressant Treatment History Form).\n* Started psychological treatment within the past 3 months with the intent of continuing treatment.\n* Patients who have previously failed escitalopram or showed intolerance to escitalopram or brexpiprazole, and patients at risk for hypomanic switch (i.e. with a history of antidepressant induced hypomania).\n\nHealthy Comparison (HC) Participants\n\nInclusion Criteria:\n\n* 18 to 65 years of age.\n* No history of psychiatric disorders (as determined by SCID-5) or significant physical conditions (e.g. arthritis, fibromyalgia).\n* Fluency in English, sufficient to complete the interviews and self-report questionnaires.","18 Years","65 Years",{"count":58,"type":22},400,[60],"PHASE4","This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).",[63],"Major Depressive Disorder",[65,66,67,68,69,70,71,72,73],"major depression","major depressive disorder","MDD","escitalopram","brexpiprazole","neuroimaging","genomics","proteomics","metabolomics","2026-06-09",{"date":76,"type":39},"2026-06-11",{"date":78,"type":39},"2023-01-20",{"date":80,"type":22},"2029-04-30",{"name":45,"class":46},10,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":90,"minAge":55,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":47},"100467293","prehabilitation-for-ovarian-cancer-patients-100467293","NCT05364879","Prehabilitation for Ovarian Cancer Patients","The Impact of Prehabilitation Exercise on Frailty and Treatment Outcomes in Ovarian Cancer Patients","Inclusion Criteria:\n\n* 18 years or older\n* Have a confirmed diagnosis of stage III or IV ovarian cancer\n* Scheduled to receive cytoreductive surgery as part of their treatment plan\n* Must have a minimum of 4-weeks between the time of study enrollment and scheduled surgery\n* Be able to attend in-person and\u002For virtual exercise sessions\n* Be fluent in English\n* Have oncologist approval\n\nExclusion Criteria:\n\n* Have already completed surgery\n* Unstable cardiac or respiratory disease, injury or any other co-morbid disease that may make it unsafe for participants to exercise\n* Significant cognitive impairment (e.g., do not have the capacity to consent, unable to follow exercise instructions)","FEMALE",{"count":92,"type":22},108,[25],"Individuals with ovarian cancer have very poor survival rates. This is because the cancer is not usually detected until it has reached advanced stages. How long an individual survives also is determined by the cancer treatment they receive. Although there are best treatment practices to improve survival, some women have other conditions that limit treatment options. One such condition seen in as many as 50% of women with advanced ovarian cancer is frailty (an age-related decline in function and health). This is a major concern as doctors will often have to change how the cancer is treated based on the patient being frail. For example, patients living with frailty are less likely to have their full tumor removed during surgery. They are also more likely to have complications with surgery, stay in the hospital longer, and recover less well from surgery overall. Patients living with frailty also are more likely to experience delays in their chemotherapy starting, receive lower doses of chemotherapy and\u002For receive fewer cycles of chemotherapy. These changes in treatment may decrease how long a patient survives after diagnosis. Thus, research is needed to explore strategies to decrease frailty in patients who require treatment for advanced ovarian cancer. An option gaining more attention is physical exercise (e.g. walking, repeatedly rising from a chair). Exercise performed before surgery, which is called prehabilitation, can improve how well a patient recovers after surgery and increase how long they survive. Research has shown that prehabilitation is very beneficial for patients undergoing surgery for heart disease. However, it is not clear whether prehabilitation works for those with advanced ovarian cancer that are going to have surgery. Therefore, the investigators want to explore how a 4+ week exercise program performed while waiting for surgery for advanced ovarian cancer changes frailty and how a patient recovers after surgery. The investigators will specifically look whether the exercise program: 1) reduces how frail a patient is before surgery; 2) improves how well the patient recovers after surgery; and 3) affects the patient's chemotherapy treatment plan. This study will provide important information about the ability of prehabilitation exercise to improve surgical and treatment outcomes in women with advanced ovarian cancer. Overall, it is believed that exercise has the potential to improve the survival of advanced ovarian cancer patients.",[96,97,98,99,100,101,102],"Prehabilitation","Exercise","Frailty","Ovarian Cancer","Surgical Complication","Treatment Outcomes","Enhanced Recovery After Surgery","2026-05-28",{"date":105,"type":39},"2026-06-01",{"date":107,"type":39},"2023-01-03",{"date":109,"type":22},"2027-08-31",{"name":45,"class":46},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":47},"100569363","investigating-the-combined-effects-of-protein-blueberries-and-exercise-on-cardiovascular-health-and-frailty-in-older-nova-scotians-100569363","NCT06693271","Investigating the Combined Effects of Protein, Blueberries, and Exercise on Cardiovascular Health and Frailty in Older Nova Scotians","The STudy on bluebeRries, prOteiN, and Exercise for improvinG Frailty and Cardiovascular Disease (STRONG)","STRONG","Inclusion Criteria:\n\n* Must be 65 years of age or above\n* Must be willing to participate in a low to moderate exercise program\n\nExclusion Criteria:\n\n* Medical and cognitive conditions that prevent participation in the intervention\n* Allergies and or dislike of blueberries and\u002For protein powder",{"count":120,"type":22},240,[25],"Cardiovascular diseases (CVD) are a leading cause of morbidity and mortality worldwide. While CVDs are predominantly diseases of aging, age itself does not predict CVD risk; people age at different rates. Frailty is a state of accelerated aging that increases the risk of adverse health outcomes. Frail people are at higher risk of developing CVDs, experiencing complications, and dying from these diseases than fit people of the same age. Indeed, frailty predicts the likelihood of developing CVD independently of traditional risk factors for CVD. It is known that older women are frailer than men and tend to express CVDs differently than men, but whether relationships between frailty and CVD are sex specific is unclear. It is possible that shared pathophysiological mechanisms such as chronic inflammation may help explain links between CVD and frailty. Importantly, the degree of frailty can be modified by lifestyle interventions. For example, sedentary lifestyles, food insecurity, and suboptimal dietary habits can exacerbate frailty whereas diet and exercise interventions can attenuate frailty.\n\nThe investigators propose that a comprehensive health strategy targeting diet and physical activity to reduce frailty will reduce the risk of cardiovascular disease (CVD), thereby promoting healthy aging. Engaging in physical activity (e.g. exercise) helps improve aerobic fitness, increase muscle mass, promote cardiac regeneration, enhance metabolic function, regulate blood pressure, improve insulin sensitivity, reduce inflammation (a key frailty mechanism), and lessen frailty. High-quality dietary protein is essential to maintain muscle mass\u002Ffunction, preserve mobility, attenuate inflammation, and reduce frailty. Packed with antioxidants such as anthocyanins and flavonoids, with high levels of fiber, vitamins, and minerals, blueberries, a local Nova Scotian food, can help lower blood pressure, improve blood vessel function, reduce inflammation, and help the body utilize dietary protein. These are critical aspects of a strong heart and healthy aging. To date, many frailty intervention studies have been limited by small sample sizes, underrepresentation of women, and\u002For by testing individual lifestyle modifications rather than synergistic effects; additionally, none have investigated how reducing frailty impacts cardiovascular outcomes. Our goal is to determine if a year-long multidomain intervention of protein, blueberries, and exercise reduces frailty and cardiovascular disease risk in older at-risk Nova Scotians of both sexes.",[124,98],"Cardiovascular Disease",[124,98,126,97,127,128,129,130,131,132],"Blueberries","Protein","Obesity","Hypertension","Hyperlipidemia","Sedentary Lifestyle","Older Adults","2026-05-19",{"date":135,"type":39},"2026-05-20",{"date":137,"type":39},"2025-12-15",{"date":139,"type":22},"2028-12-31",{"name":45,"class":46},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100616989","testing-the-feasibility-of-a-virtual-application-to-support-breast-and-colorectal-cancer-survivors-100616989","NCT07312786","Testing the Feasibility of a Virtual Application to Support Breast and Colorectal Cancer Survivors","Testing the Feasibility of a Virtual Application to Support Breast and Colorectal Cancer Survivors After Completing Primary Treatment","Inclusion Criteria:\n\n* Adults older than 18 years, capable of providing informed consent\n* Diagnosed with stage I-III breast or colorectal cancer, and have completed primary treatment for their cancer (surgery and\u002For adjuvant systemic or radiation therapy) 6 months - 5 years ago",{"count":149,"type":22},60,[25],"The goal of this study is to determine the feasibility of implementing a mobile health application for breast and colorectal cancer survivors following primary treatment. Developed in collaboration with Seamless MD, the intervention acts as an information hub, providing users with timely and evidence-based information related to follow-up care as well as health system\u002Fcommunity-based resources and programs to meet their needs during this period of care. The goal of the intervention is to encourage open communication regarding survivorship expectations and provide survivors with appropriate information and support to meet their needs.\n\nThis study will:\n\n1. Test the feasibility of implementing the virtual intervention at two cancer centres in Atlantic Canada (Nova Scotia and New Brunswick)\n2. Gather feedback regarding the intervention from cancer survivors and healthcare providers.\n\nParticipants will have access to the intervention for a period of six months. Questionnaires will be distributed to participants through the intervention at baseline, 90 days, and 180 days to assess user experience. Semi-structured interviews will be conducted with select survivor participants and healthcare providers (oncology and primary care) to determine the feasibility and acceptability of this intervention.",[153,154],"Breast Cancer Survivor","Colorectal Cancer Survivors",[156,157,158,159],"Cancer Survivorship","SeamlessMD","Supported self-management","Survivorship app","2026-05-13",{"date":162,"type":39},"2026-05-14",{"date":164,"type":39},"2026-04-20",{"date":166,"type":22},"2027-12",{"name":45,"class":46},2,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":18,"sex":19,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":168},"100482627","surgical-treatment-of-recurrent-shoulder-dislocations-100482627","NCT05564494","Surgical Treatment of Recurrent Shoulder Dislocations","The Arthroscopic Treatment of Anterior Shoulder Instability (ATRASI): A Pilot Multicentre Randomized Controlled Trial","Inclusion Criteria:\n\n* Recurrent anterior glenohumeral dislocation (two or more incidents)\n* Presence of glenoid and\u002For humerus bone loss on imaging (x Ray, CT or MRI)\n\nExclusion Criteria:\n\n* Uncontrolled diabetes (Hgb A1C \\>7%)\n* Prior surgery of affected shoulder\n* Pregnancy\n* Multidirectional instability\n* Posterior instability\n* Paralysis of the shoulder\n* Cancer\n* Severe systemic illness\n* Presence of massive rotator cuff tear\n* Patients that present with \\\u003C 10% or \\> 25% bone loss under preoperative imaging.\n* Generalized laxity (\\>5\u002F9 Beighton Score)","16 Years","40 Years",{"count":179,"type":22},200,[25],"This is a pilot multi-centre, double blinded randomized controlled trial. The primary outcome of this pilot trial will be feasibility. Prior to conducting a large definitive trial, the investigators will conduct this pilot trial comparing arthroscopic Bankart repair with arthroscopic anatomic glenoid reconstruction (AAGR), evaluating recurrent dislocation rates and functional outcomes over a 24-month period. The feasibility objectives are: (1) to evaluate the investigators ability to recruit patients across multiple sites and (2) to assess study protocol adherence and ability to follow patients to 24 months. Clinical objectives for the pilot trial are exploratory only. The investigators wish to gather means and standard deviations for clinical outcomes to power their future definitive trial. The objectives of the definitive trial will include a comparison of patient-reported outcomes at the two-year post-operative time point, differences in recurrence rates, complication rates, functional shoulder assessments, and return to work\u002Fsport.",[183],"Shoulder Instability",[185,183,186],"Arthroscopy","Multiple Dislocations","2026-04-28",{"date":189,"type":39},"2026-05-04",{"date":191,"type":39},"2023-04-25",{"date":139,"type":22},{"name":45,"class":46},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":19,"minAge":176,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":168},"100597315","effects-of-action-based-cognitive-remediation-on-substance-misuse-in-early-phase-psychosis-100597315","NCT07056894","Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis","Evaluating a Brief Virtual Cognitive Remediation Therapy Intervention for Those With Early Phase Psychosis and Substance Misuse in NS\u002FNL: Addressing Challenges in Underserviced Areas","Inclusion Criteria:\n\n* This study will enroll individuals 16-30 years of age from the Early Intervention Services for Psychosis programs in Nova Scotia and the Psychosis Intervention Early Recovery program in Newfoundland\n* Diagnosed with a primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder, and unspecified schizophrenia spectrum disorder)\n* Less than 5 years of psychotic illness\n* Has problematic alcohol and\u002For cannabis use (score of 8 or higher on the World Health Organization Alcohol Use Disorders Identification Test (WHO-AUDIT) or Cannabis Use Disorder Identification Test-Revised (CUDIT-R)).\n\nExclusion Criteria:\n\n* Current stimulant use disorder","30 Years",{"count":203,"type":22},50,[25],"Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in significant challenges for individuals and their families, including difficulties with thinking, relationships, and overall well-being. They also carry significant economic costs, both for health care and lost productivity. Early intervention services have been shown to improve outcomes when provided during the first few years of illness known as early phase psychosis (EPP). However, substance use, especially alcohol and cannabis, can interfere with the effectiveness of these services. Many young people with psychosis misuse these substances, which can harm brain development, worsen symptoms, reduce medication use, and lower quality of life. Despite understanding the risks, there are few effective ways to reduce substance misuse in patients with EPP.\n\nOne promising approach to reducing substance misuse in this population is cognitive remediation therapy, which helps improve thinking skills and everyday functioning. Studies have found that some cognitive remediation therapies can help reduce alcohol use in chronic schizophrenia, but there is limited research targeting the EPP population. Our research team at the Nova Scotia Early Psychosis Program recently completed a pilot study that indicated a therapy called Cognitive Enhancement Therapy (CET) helped participants reduce their problematic alcohol and cannabis use. However, challenges with recruitment and lower attendance rates noted towards the end of the 6-month therapy course suggests that patients with EPP would benefit more from a therapy with a shorter timeframe. Alternatively, Action-Based Cognitive Remediation (ABCR) targets the same cognitive domains believed to help reduce substance use as CET, but has a shorter, more concise schedule. ABCR cover 16 sessions delivered bi-weekly for 2 months, compared to 45 sessions over 6 months of CET. ABCR has been tested in the EPP population and has shown positive results when delivered in person, hybrid and remotely. Although this therapy is demonstrating benefits for patients including improvement in daily functioning and social cognition, its effects on substance misuse have not been researched. This study aims to investigate whether treatment with ABCR helps patients with EPP reduce their alcohol and\u002For cannabis use.",[207,208,209],"Psychosis","Alcohol Use Disorder","Cannabis Use Disorder",[211,212,213,214],"alcohol","cannabis","action based cognitive remediation","psychosis","2026-04-01",{"date":217,"type":39},"2026-04-07",{"date":219,"type":22},"2026-03-27",{"date":221,"type":22},"2028-03-31",{"name":45,"class":46},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":168},"100593087","phase-4-cannabis-potency-effects-on-brain-white-matter-in-early-phase-psychosis-100593087","NCT07001878","Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis","Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis: A Pilot Feasibility Treatment Study","Inclusion Criteria:\n\n* This study will enroll individuals 18-25 years of age from the Nova Scotia Early Psychosis Program\n\nExclusion Criteria:\n\n* Current stimulant use disorder","25 Years",{"count":232,"type":22},24,[60],"Canada reports some of the highest rates of cannabis use in our youth and young adult populations, among all the developed countries. Recent Health Canada surveys report that 27% of 16-19-year-olds and 32% of 20-24-year-olds have used cannabis in the past 30 days, with 16-24-year-olds showing the highest rates of daily or near-daily use. Unfortunately, cannabis use has also been found to be a risk factor for the development of a psychotic disorder in emerging adults, and in those who develop psychosis and continue cannabis use, there is a significant effect on long term outcomes. This includes the severity of symptoms, risks of relapse (being hospitalized) and not reaching a level of functioning that would be expected. Lifetime experience with cannabis is greater than 80% in young adults with early phase psychosis (EPP; the first 5 years of a psychosis illness) with up to 30% of Canadian EPP patients meeting criteria for a diagnosis of cannabis use disorder (CUD) at entry to care. A recent Canadian population-based study found that cannabis use disorder associated to psychosis has risen from 3.7% pre-2018 to 10.3% at present. There has been a significant increase in Δ9-tetrahydrocannabinol (THC) levels in cannabis products available globally over the years, with popular cannabis products available start as high as 18% THC in Canada. However high potency cannabis carries a more significant risk for psychosis development, as well as higher risk for cannabis dependence and other severe mental health issues.\n\nA major gap in the research is a specific focus on cannabis potency on brain white matter (WM) in youth and young adults, and if there are any potential treatment strategies that could be used to influence any of these cannabis WM effects. To address this, a medication called metformin, that is already used in psychosis to help with side effects of antipsychotic medications, will be used as it has also shown promise to influence WM changes in other illnesses. This project is thus focused on naturalistic cannabis potency effects on WM in emerging adults in EPP (divided into three groups; those using high potency cannabis, low potency cannabis, and minimal cannabis use) and treating them with metformin for 6 months and assessing effects on neuroimaging, cognitive and clinical variables.\n\nThe purpose of this pilot feasibility study is to inform the development\u002Frefinement of an intervention protocol, and not to test potential effects or mechanisms as the sample size will have insufficient power to perform an in-depth analysis. The results of this work will inform our research strategy development and assess feasibility of our novel methodological approach.\n\nParticipants will:\n\n1. Visit the clinic at baseline, 3 months (only Timeline Follow-Back Assessment administered), and 6 months post baseline to complete substance use and mental health questionnaires, and cognitive assessments\n2. Complete an MRI scan at baseline and 6 months\n3. Take Metformin every day for 6 months",[207,236],"Cannabis Use",[212,238,239,240],"metformin","early phase psychosis","potency",{"date":217,"type":39},{"date":243,"type":39},"2025-03-18",{"date":245,"type":22},"2026-12-01",{"name":45,"class":46},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":4},"100560321","knee-hip-surgery-wait-list-support-program-100560321","NCT06575621","Knee-hip Surgery Wait-list Support Program","Re-imagining Hip and Knee Arthroplasty Wait-list in Nova Scotia: Pre-surgery Support Program","Inclusion Criteria:\n\n* On surgery wait list for total hip or knee arthroplasty at Valley Regional Hospital\n* 18+ and able to provide informed consent\n* Anticipated surgery time 8-16 weeks after the study start date\n\nExclusion Criteria:\n\n* Any contraindications or exclusions identified through the assessment process that are outside thresholds for acceptable surgery risk",{"count":203,"type":22},[25],"This project will outline a pre-surgery support program that identifies risk factors related to poor surgical outcomes and recommends actions to improve these before surgery.\n\nThe main questions this study attempts to answer are:\n\n1. Is a formalized knee-hip pre-surgery support program feasible, measured by recruitment rate, adherence, and completion rate?\n2. Does the support program improve surgical risk factors including hemoglobin A1c (HB A1C), blood pressure, hemoglobin, estimated glomerular filtration rate (eGFR), frailty score, and physical fitness and function (measured with the 2-minute step test and 30s second sit to stand test)?\n\nParticipants will participate in education, medical navigation, and exercise.",[258,259],"Knee Arthropathy","Hip Arthropathy",[261,262,263,264,265],"surgery","knee","hip","exercise","risk factors","NOT_YET_RECRUITING","2026-03-19",{"date":269,"type":39},"2026-03-20",{"date":271,"type":22},"2026-06-15",{"date":273,"type":22},"2027-08-30",{"name":45,"class":46},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":291,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":47},"100605967","improving-kidney-care-in-type-2-diabetes-a-study-of-pharmacist-prescribing-versus-usual-care-100605967","NCT07169422","Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care","Community Pharmacist Prescription for Diabetic Kidney Disease (Rx4DKD): A Randomized Controlled Trial and Implementation Study","RX4DKD","Inclusion Criteria:\n\n* Adults ≥18 years with T2D and DKD (eGFR≥ 30-60 ml\u002Fmin\u002F1.73m2 and\u002For UACR≥3 mg\u002Fmmol)\n* Adults who do not have primary care provider,\n* Adults who are eligible for initiation of treatment with RASi, SGLT2i or nsMRA\n\nExclusion Criteria:\n\n* Hypotension\n* Type 1 diabetes\n* History of allergy or intolerance to either, renin angiotensin system inhibitor (RASi), SGLT2 inhibitor (SGLT2i) and nonsteroidal mineralocorticoid receptor antagonist (nsMRA).\n* Already receiving all three medications: RASi, SGLT2i, and nsMRA .\n* Exceed algorithm thresholds for potassium levels or eGFR less than 30 mL\u002Fmin\u002F1.73m²\n* Limited life expectancy of less than 1 year\n* Followed by a subspecialty physician (e.g., nephrologist or endocrinologist)\n* Unable to give consent",{"count":284,"type":22},120,[25],"Type 2 diabetes is the leading cause of chronic kidney disease, which can result in serious complications such as kidney failure and heart disease. Although effective medications exist to slow the progression of kidney damage, they are often underused in primary care, particularly for individuals without a regular family doctor. In response to this gap, 46 community pharmacy-led primary care clinics were launched across Nova Scotia in 2023 to serve under-resourced areas. Pharmacists at these clinics can prescribe for many chronic conditions, but currently not for diabetic kidney disease. To address this, the research team collaborated with kidney, diabetes, and primary care experts, patient partners and regulatory bodies to develop and validate step-by-step prescribing guide (called algorithms) that support pharmacists in identifying and managing diabetic kidney disease. All medications included are approved, publicly funded in Nova Scotia, target people with earlier categories of diabetic kidney disease and includebuilt-in safety monitoring, nurse practitioner consultation or referral to a kidney doctor. This study will evaluate whether these algorithms improve kidney protective medication use which have shown to be beneficial for people with diabetes and kidney disease. The investigators will recruit 120 adults with type 2 diabetes from a provincial diabetes registry who do not have a primary care provider and screen them at pharmacy clinics for diabetic kidney disease. Those eligible and who wish to participate will be randomly assigned to either an intervention group receiving pharmacist-led care using the algorithms or a control group receiving usual care through walk-in, mobile, or virtual clinics. The investigators will measure how many patients begin and continue recommended medications, as well as any medication-related side effects or hospitalizations. Pharmacist participants will also complete a survey to identify what helps or hinders implementation in real-world practice. This research is relevant because it aims to expand access to kidney-protective treatments for people with diabetes, especially those with early forms of diabetic kidney disease who do not have regular access to primary care provider, ultimately improving long-term health outcomes.",[288,289,290],"Diabetic Kidney Disease","Type 2 Diabetes","Chronic Kidney Disease",[292,293,294,295,296,297,298],"diabetic kidney disease","pharmacist-led prescribing","type 2 diabetes","guideline directed medical treatments","pharmacy care models","decision support algorithym","chronic kidney disease","2026-03-16",{"date":301,"type":39},"2026-03-18",{"date":303,"type":22},"2026-03-01",{"date":305,"type":22},"2028-07-01",{"name":45,"class":46},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":47},"100582548","virtual-reality-rehabilitation-for-stroke-patients-in-the-hospital-and-at-home-100582548","NCT06864741","Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home.","Acute Stroke Rehabilitation Using a Low-cost Virtual Reality Platform: a Pilot Study.","Inclusion Criteria:\n\n* clinical diagnosis of first-time ischemic stroke involving the middle cerebral artery, confirmed by CT or MRI;\n* score between 6 and 40 on Fugl-Meyer Assessment's Upper Limb Extremity Subscore (FM - UE), indicating moderate to severe motor deficit;\n* ability and willingness to provide consent (score of 18 or more on the Montreal Cognitive Assessment) or assent (for scores lower than 18 on MoCA with consent provided by an authorized third party with the necessary legal authority to consent on behalf of patient)\n* INPATIENT ARM: less than 5 weeks since stroke onset with admission to Valley Regional Hospital in Kentville, NS, Canada\n* OUTPATIENT ARM: less than 3 months since stroke onset with discharge to home setting located within 1 hour drive of Valley Regional Hospital in Kentville, NS, Canada\n\nExclusion Criteria:\n\n* brainstem, cerebellar or bilateral stroke lesion\n* a secondary neurological condition (e.g., Parkinson's disease)\n* musculoskeletal injuries interfering with task performance\n* an uncorrected visual deficit due to stroke or other etiologies\n* apraxia as identified by clinical assessment",{"count":315,"type":22},40,[25],"The goal of this clinical trial is to test whether a low-cost virtual reality (VR) motor rehabilitation platform can improve motor recovery in people recovering from a first-time ischemic stroke both in the hospital and at home. The study focuses on adults aged 18 and older who have experienced moderate to severe upper limb motor deficits.\n\nThe main questions it aims to answer are:\n\n* Can VR-based motor therapy improve upper limb motor function compared to standard care?\n* Is VR-based motor therapy a feasible and acceptable treatment option for stroke patients?\n\nResearchers will compare patients receiving VR therapy to those receiving standard care to see if the VR therapy leads to greater improvements in motor recovery and more positive patient experiences.\n\nParticipants will:\n\n* Complete standardized assessments of motor function and quality of life at multiple time points.\n* Participate in VR therapy sessions (if in the treatment group), using gamified activities designed to improve upper limb movement.\n* Provide feedback on their experience with the VR system, including ease of use, motion sickness, and engagement.\n\nThis study will help determine whether VR-based rehabilitation can be a practical, effective way to improve access to therapy and recovery outcomes for stroke patients, especially in rural settings with limited rehabilitation resources.",[319],"Stroke Acute",[321,322,323,324],"stroke","rehabilitation","motor disorder","virtual reality",{"date":301,"type":39},{"date":327,"type":39},"2025-10-15",{"date":329,"type":22},"2027-06",{"name":45,"class":46},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":351,"leadSponsor":353,"locationsCount":47},"100603949","yoga-fit-protocol-for-a-crossover-trial-investigating-the-feasibility-and-impact-of-yoga-for-people-with-stroke-100603949","NCT07143162","YOGA-FIT: Protocol for a Crossover Trial Investigating the Feasibility and Impact of Yoga for People With Stroke","YOGA-FIT","Inclusion Criteria:\n\nParticipants will be eligible if they are an adult (aged 18 or older), living with late subacute or chronic stroke (minimum of three months post stroke), residing in Nova Scotia, capable of walking at least 10-metres independently, with supervision, or with the use of an aid or orthotic, and medically stable for eight weeks prior to the baseline visit. Participants must also be able to follow a three-step command for the purpose of yoga class instruction as recommended by our lead yoga instructor.\n\nExclusion Criteria:\n\nParticipants with severe neglect or other issues affecting their safety and participation will be excluded. Participants with cardiovascular, orthopedic, or neurological diseases other than stroke, impacting walking, balance, and mobility will be excluded. Participants who do not have a stable and reliable internet connection will be excluded.",{"count":315,"type":22},[25],"The primary objective of this mixed-methods pilot crossover study is to determine the feasibility (participant satisfaction, recruitment rate, participant and assessor burden, adherence, equipment and technology issues, and safety) of virtual and in-person LYB yoga for adult people with lived experience of stroke in Nova Scotia who are at least three months post stroke.\n\nThe secondary objective is to estimate the efficacy of virtual and in-person yoga for improving balance, walking, mobility, mental health (anxiety and depression), and other health outcomes (pain, sleep, health perception, and falls).\n\nThe tertiary objective is to estimate the extent to which cognitive function, fatigue, and health-related quality of life co-evolve with our secondary outcomes.\n\nParticipants will engage in LYB Yoga virtual and in-person classes for 90 minutes each, twice per week, as well as one 60-minute recorded class completed on their own time.",[342],"Stroke",[342,344,345,346],"Yoga","LoveYourBrain","Virtual rehabilitation","2026-03-11",{"date":349,"type":39},"2026-03-12",{"date":215,"type":22},{"date":352,"type":22},"2027-12-10",{"name":45,"class":46},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":47},"100613460","a-mindfulness-based-stress-reduction-program-for-ibd-100613460","NCT07266883","A Mindfulness-based Stress Reduction Program for IBD","Targeting the Brain-gut Axis in Inflammatory Bowel Diseases: Implementation and Exploration of Mechanism and Early Effectiveness of a Mindfulness-based Stress Reduction Program","MBSRforIBD","Inclusion Criteria:\n\n* 18 years of age or older\n* having a known diagnosis of IBD that is mildly to moderately active\n\nExclusion Criteria:\n\n* Pediatric participants",{"count":5,"type":22},[25],"The gut-brain connection is important for good health and when it is disrupted it can worsen existing chronic disease. Studies have shown that chronic stress has negative effects on the gastrointestinal tract such as inflammation and disruption of the beneficial bacteria that live there. These negative effects of chronic stress can lead to flare-ups of IBD. Mindfulness-based stress reduction (MBSR) is a structured 8 week program that aims to reduce stress by teaching mindfulness techniques. Recent research in people living with IBD suggests that MBSR could improve one's quality of life by reducing stress levels. The study aims to investigate the effects of MBSR on both the mental health of people living with IBD, and their physical health. The investigators are studying people who are participating in an MBSR program as well as those receiving standard of care at the QEII Health Sciences Centre. This study will assess how effective the MBSR program is compared to standard of care at reducing distress and signs of stress and inflammation in people living with IBD. This study aims to provide valuable insights into how mindfulness techniques could be used to support individuals living with IBD. Ultimately, this research aims to improve quality of life and health outcomes for people affected by this challenging condition.",[366],"Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis)",[368,369,370],"IBD","psychological distress","mindfulness","2026-02-25",{"date":373,"type":39},"2026-02-27",{"date":375,"type":22},"2026-02-01",{"date":377,"type":22},"2027-02-01",{"name":45,"class":46},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":19,"minAge":387,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":396,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":403,"leadSponsor":405,"locationsCount":4},"100591975","continuous-erector-spinae-block-for-analgesia-following-lumbar-decompression-100591975","NCT06987409","Continuous Erector Spinae Block for Analgesia Following Lumbar Decompression","Continuous Erector Spinae Block for Analgesia Following Lumbar Decompression: A Randomized Controlled Study","Lumbar-ESP","Inclusion Criteria:\n\n* Adult (aged \\>18 years) patients\n* Undergoing lumbar decompression surgery +\u002F- fusion\n* Under the orthopedic surgery team\n\nExclusion Criteria:\n\n* Surgery on an emergency basis (level 1, 2 or 3; \\\u003C8 hours)\n* An ejection fraction \\\u003C30%\n* Severe pre-existing liver disease (Child B or C)\n* Severe kidney disease (Glomerular filtration rate (GFR) \\\u003C30 (mL\u002Fmin\u002F1·73m²))\n* An allergy to ropivacaine\n* Weight \\\u003C50 kg\n* Unable to provide valid consent to study prior to surgery","19 Years",{"count":389,"type":22},100,[25],"Lumbar spinal surgery is common, and the incidence of spinal fusion has increased dramatically over the past three decades. Patients requiring spinal surgery are typically prescribed several analgesics, (including opioids) while awaiting surgery. Postoperatively, use of high doses of opioids or anti-inflammatory medications have drawbacks. Severe post-operative pain is reported by 45-80% of patients and rates are generally higher in the opioid tolerant patients.\n\nRegional anesthesia (blocking nerves with local anesthetics) works locally, thereby avoiding many side effects associated with other analgesics. One type of nerve block is called erector spinae plane block (ESP). Single injection nerve blocks have been found to decrease pain, nausea, and opioid consumption, while increasing patient satisfaction and quality of recovery. However, these effects only last for 24 hours or less while the worst pain occurs around 36 hours after surgery. Surgeon-placed indwelling catheters could allow infusions of local anesthetics for 54 hours.\n\nThis randomized control trial seeks to assess the effectiveness of surgeon-placed ESP catheters for pain control after lumbar spine surgery.\n\nHypothesis: Patients receiving a cESP will have less pain, improved quality of recovery, and opioid use following lumbar fusion surgery than those receiving current standard of care pain management.\n\nMethodology: Adult patients undergoing lumbar spine surgery under orthopedic surgery in Halifax will be eligible. The study will include 100 participants, randomly assigned to 2 study arms of 50 participants (1:1 basis to Ropivacaine and placebo groups). At the end of surgery, the surgeon will place the ESP catheters in all study patients under sterile conditions before closing the wound. Ropivacaine 0.5% or normal saline (placebo) 15ml will be injected through each catheter (total 30ml). In the postanesthetic care unit (PACU), two elastomeric pumps will be attached to the ESP catheters. These will be filled with either Ropivacaine 0.2% or normal saline (placebo). The elastomeric pumps are small bottle that patients can carry with them after discharge home. The pumps automatically run at an infusion rate of 10 ml\u002Fhr for 54 hours. All patients will also receive the standard of care for pain management for this patient population, which is opioid based with acetaminophen. A quality of recovery (QoR-15) questionnaire will be completed at 72 hours post-operatively. Pain, catheter complication, and opioid use data will be gathered from the patient's charts at 24, 48, and 72 hours post-operatively. At 3- and 6-month follow-ups, patients will complete the Brief Pain Inventory questionnaire. We will analyze differences in pain and opioid consumption at 24, 48, and 72 hours, quality of recovery index scores at 72 hours, postoperative complication rates, and persistent pain at 3 and 6 months.",[393,394,395],"Lumbar Spinal Stenosis","Lumbar Radiculopathy","Persistent Postsurgical Pain",[397,398],"Erector spinae block","Regional anesthesia","2026-02-13",{"date":401,"type":39},"2026-02-17",{"date":245,"type":22},{"date":404,"type":22},"2028-08-01",{"name":45,"class":46},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":47},"100613923","treating-atrial-fibrillation-in-heart-failure-with-preserved-ejection-fraction-ablation-or-medication-100613923","NCT07272902","Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication","A Randomized Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control Trial in Patients With Heart Failure and Preserved Ejection Fraction (CABANA-RAFT HF): A Pilot Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of atrial fibrillation (documented on Holter, rhythm strip, or ECG)\n* New York Heart Association (NYHA) class II-III heart failure\n* Left ventricular ejection fraction (LVEF) \\>40%\n* Meet specific NT-proBNP criteria:\n* If HF hospitalization within 6 months prior to screening: NT-proBNP \\>200 pg\u002Fml (if not in AF at screening) or \\>600 pg\u002Fml (if in AF at screening)\n* Otherwise: NT-proBNP \\>300 pg\u002Fml (if not in AF at screening) or \\>900 pg\u002Fml (if in AF at screening)\n* On stable guideline-directed medical therapy for ≥1 month\n* On stable diuretic dose for ≥2 weeks\n* Suitable for either ablation-based rhythm control or rate control strategy\n\nExclusion Criteria:\n\n* Permanent atrial fibrillation diagnosis\n* Prior catheter ablation for atrial fibrillation\n* NYHA class IV heart failure\n* Rheumatic heart disease\n* Moderate or severe mitral stenosis\n* Mechanical mitral valve\n* Severe aortic stenosis or severe aortic\u002Fmitral regurgitation\n* Renal failure requiring dialysis\n* Contraindication to oral anticoagulation\n* Infiltrative cardiomyopathies\n* Complex congenital heart disease\n* Untreated thyroid disease\n* Acute coronary syndrome or coronary artery bypass surgery within 12 weeks\n* Participation in another clinical trial\n* Inability to provide informed consent\n* Other serious non-cardiovascular condition with life expectancy ≤1 year\n* Age \\\u003C18 years",{"count":414,"type":22},84,[25],"This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.",[418,419,420,421,422],"Atrial Fibrillation (AF)","Heart Failure With Mildly Reduced Ejection Fraction","Heart Failure With Preserved Ejection Fraction (HFPEF)","Rate Control","Rhythm Control","2026-02-12",{"date":401,"type":39},{"date":426,"type":39},"2026-01-01",{"date":428,"type":22},"2027-10",{"name":45,"class":46},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":444,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":4},"100611393","phase-4-comparing-spinal-anesthesia-with-1-chloroprocaine-versus-1-mepivacaine-in-patients-undergoing-outpatient-primary-total-knee-arthroplasty-100611393","NCT07239999","Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee Arthroplasty","Randomized Controlled Trial Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee Arthroplasty","Inclusion Criteria:\n\n* ASA I-III\n* Elective outpatient TKA\n* BMI less than 40\n* Ability to provide surgical consent\n\nExclusion Criteria:\n\n* Patient refusal\n* Opioid tolerant\n* Any contraindications to spinal anesthesia\n* Chronic opioid use 3months or more",{"count":438,"type":22},170,[60],"This study or clinical trial looking to compare 2 types of freezing medications injected into the spinal fluid at the lower back between the vertebrae in patients going to have total knee replacement surgery to check for early legs movement, early discharge from recovery room, walking and hospital discharge. This could save hospital cost of such procedures.",[442,443],"Recovery Period","Anesthesia",[445,446,447,448],"Spinal anesthesia","Outpatient total knee arthroplasty","Mepivacaine","Chloroprocaine","2026-02-04",{"date":451,"type":39},"2026-02-06",{"date":453,"type":22},"2026-03-31",{"date":455,"type":22},"2027-06-15",{"name":45,"class":46},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":466,"briefSummary":467,"conditions":468,"keywords":473,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":4},"100619164","comprehensive-geriatric-assessment-in-primary-care-100619164","NCT07341061","Comprehensive Geriatric Assessment in Primary Care","Comprehensive Geriatric Assessment in Primary Care for Older Adults Across Levels of Frailty","PC-CGA","Inclusion Criteria:\n\n* Older adult patients receiving care at the Dalhousie Family Medicine Clinic and scheduled to undergo an eCGA as part of routine primary care.\n* Fluent in English and able to respond to interview and questionnaire items.\n* Able to provide informed consent; or, if judged unable to consent, able to provide assent AND has a substitute decision maker (SDM) who is willing to provide informed consent on their behalf.\n* (PAHA sub-study) Enrolled in the main eCGA study, willing to participate in a personalized physical activity- program, and available for follow-up contact.\n\nExclusion Criteria:\n\n* Not scheduled for, or not receiving, an eCGA at the investigator's family medicine clinic.\n* Unable to communicate in English, such that questionnaires and interviews cannot be completed.\n* Unable to provide informed consent and no SDM available or willing to consent on the patient's behalf.\n* (PAHA sub-study) Deemed unsuitable for the physical activity intervention by the treating family physician (e.g., medical or functional condition that, in the physician's judgment, makes participation in light-moderate exercise unsafe).",{"count":284,"type":22},[25],"This study evaluates the feasibility and acceptability of implementing the electronic Comprehensive Geriatric Assessment (eCGA) in primary care for adults aged 65 years and older. The study examines how frailty changes over 12 months, how patient self-assessments compare with physician assessments, and how patients perceive the value of the eCGA when used as part of routine care.\n\nThe study also includes an interventional randomized sub-study (PAHA), in which eligible participants receive a personalized physical activity program developed by a Clinical Exercise Physiologist. Participants are randomized to either an immediate-start or delayed-start exercise group, allowing assessment of the effects of a tailored activity intervention on frailty, physical activity participation, and goal attainment.\n\nFindings will inform how eCGA tools and personalized activity interventions can be integrated into primary care to support healthy aging and frailty management.",[98,469,470,471,472,131],"Aging","Geriatric Syndromes","Mobility Limitation","Functional Decline",[98,474,475,476,477,478,132,479,480,481,482],"eCGA","electronic Comprehensive Geriatric Assessment","Primary Care","Frailty Index","Clinical Frailty Scale","Healthy Aging","Physical Activity Intervention","Exercise Intervention","Geriatric Assessment","2026-01-05",{"date":485,"type":39},"2026-01-14",{"date":487,"type":22},"2026-01-12",{"date":489,"type":22},"2029-01-12",{"name":45,"class":46},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":501,"conditions":502,"keywords":506,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":47},"100617737","hearts-in-sync--cardiowatch-287-2-100617737","NCT07322510","HEARTS in Sync + CardioWatch 287-2","Health Behaviour Change, Education on Risk Factor Reduction, Physical Activity Guidance, and Nutrition Counselling With a Remote Team to Support Patient Progress Using Technology in Synchronization With Medication Management and CardioWatch 287-2. (HEARTS in Sync + CardioWatch 287-2)","Inclusion Criteria:\n\n* Patients who meet CR inclusion criteria requirements and who are enrolling in virtual cardiac rehab program, HEARTS in Sync, in Nova Scotia.\n\nExclusion Criteria:\n\nPhones that are not compatible with the Corsano system.\n\n* Huawei P8 Lite\n* Huawei P9 Lite\n* Xiaomi Mi 6\n* Huawei P20 Lite\n* Apple iOS version lower than 14.5\n* Android OS version lower than 8.0\n* Android or Apple devices without Bluetooth® 5.0 Low Energy capability",{"count":499,"type":22},216,[25],"The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program.\n\nThe wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program.\n\nThe primary objectives of this study are to:\n\n1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not.\n2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by:\n\n   1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates,\n   2. Evaluating change in patient bloodwork outcomes,\n   3. Measuring change is physical ability,\n   4. Analyzing changes in eating behaviours, and\n   5. Examining quality of life using validated tools.\n3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by:\n\n   1. Assessing device adherence\n   2. Reviewing patient feedback survey, and\n   3. Determining if clinician team were able to access and interpret data collected throughout the program\n\nThe secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program.\n\nThis research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.",[503,124,504,505],"Wearable Device","ASCVD Management","CHF - Congestive Heart Failure",[507,508,509],"virtual cardiac rehabilitation","wearable device","remote monitoring","2025-12-23",{"date":512,"type":39},"2026-01-07",{"date":514,"type":22},"2026-02",{"date":516,"type":22},"2029-02",{"name":45,"class":46},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":531,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":47},"100554158","using-omnidirectional-virtual-reality-and-treadmill-training-for-chronic-stroke-100554158","NCT06495450","Using Omnidirectional Virtual Reality and Treadmill Training for Chronic Stroke","PROVE-VR: A Pilot Randomized Trial Using Omnidirectional Virtual Reality and Treadmill Training for Chronic Stroke Survivors","PROVE","Inclusion Criteria\n\n* Age ≥ 18\n* Stroke ≥ 6 months ago (confirmed with chart review)\n* Living within 50 km of Halifax, Nova Scotia\n* Functional Ambulation Category of 3 or greater on a scale of 0-5, to ensure the participant is able to walk with supervision or independently. This criterion was selected to ensure participants could safely participate in the intervention.\n* Ability to participate in low-moderate intensity aerobic or strengthening exercise for ≥ 15 minutes to ensure participants can tolerate intervention sessions of 30-45 minutes, with activity breaks, in keeping with previous stroke rehabilitation studies.\n* No uncorrected visual deficits or spatial neglect\n* No cardiovascular, orthopedic, or neurological diseases other than stroke impacting walking or balance\n* Can follow simple instructions\n* Score of \\\u003C 27 on the adapted Motion Sickness Susceptibility Scale-Short based on established normative values indicating more than moderate susceptibility to motion sickness.\n\nExclusion Criteria:\n\n* Unstable serious medical condition\n* Resting blood pressure \\>180\u002F100mmHg\n* History of abnormal untreated heart rhythm\n* Pregnancy\n* Condition limiting ability to complete or tolerate the exercises without major program modifications (e.g., chronic low back pain)\n* Serious comorbid condition that would affect participation in the intervention (e.g., active cancer, severe heart disease)\n* Severe loss of hearing or speech that would preclude VR use\n* Participant weight more than 264 lbs (weight limit for Virtualizer Elite 2 treadmill)\n* Participating in another formal lower limb exercise program \\> 1 day per week\n* History of QT prolongation or using potential QT prolonging drugs",{"count":527,"type":22},30,[25],"The primary objective of this pilot randomized controlled trial (RCT) is to test the feasibility (consent rate, retention rate, participant burden, adherence, technical issues, safety) and usability (system usability scale, SUS) of Omnidirectional treadmill Virtual Reality training (omni-VR) among chronic stroke survivors. Our secondary objective is to (1) estimate the extent to which cognition, brain activation during a dual task activity, walking ability, and dynamic balance change after 3 months of training among intervention participants (omni-VR) and traditional exercise controls, and (2) estimate the extent to which health-related quality of life and motivation co-evolve with our secondary outcomes.\n\nResearchers will compare the intervention group and control group to evaluate the impact of omni-VR on cognition and physical function among stroke survivors.\n\nParticipants will:\n\n* undergo a 45-minute training session 3 times per week for 12 weeks\n* intervention group: omni-VR\n* control group: traditional exercise program (strengthening and walking activities)",[342],[532,533,534],"Virtual Reality","Stroke rehabilitation","Omnidirectional treadmill","2025-12-09",{"date":537,"type":39},"2025-12-16",{"date":539,"type":39},"2025-04-28",{"date":541,"type":22},"2026-09-06",{"name":45,"class":46},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":23,"phases":552,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":4},"100603991","safety-and-effectiveness-of-preserflo-and-xen-stents-with-or-without-amniotic-membrane-in-glaucoma-surgery-100603991","NCT07143708","Safety and Effectiveness of PreserFlo and XEN Stents With or Without Amniotic Membrane in Glaucoma Surgery","Comparison of the Safety and Efficacy of PreserFlo MicroShunt and XEN Stent Alone Versus With Amniotic Membrane in Glaucoma Surgery","Inclusion Criteria:\n\n1. Age 18 years and older\n2. Patients selected for PreserFlo microshunt surgery and XEN stent alone or in combination with cataract surgery.\n3. Ability to comprehend the study procedures\n\nExclusion Criteria:\n\n1. Unwilling or unable to give consent\n2. Unable to come for scheduled post-operative visits\n3. Pregnant or nursing women\n4. Previous cyclodestructive procedures, scleral buckling procedures, or presence of silicone oil\n5. Conjunctival scarring precluding a glaucoma surgery superiorly\n6. Active iris neovascularization or active proliferative retinopathy\n7. Vitreous in the anterior chamber for which a vitrectomy is anticipated.\n8. Previous trabeculectomy, tube-shunt implantation, or surgeries that shunt aqueous outflow into the subconjunctival space",{"count":551,"type":22},156,[25],"Glaucoma is one of the leading causes of permanent blindness in the world. It happens when the optic nerve-the connection between the eye and the brain-is damaged. As this damage gets worse, vision is slowly lost.\n\nGlaucoma treatments often begin with eye drops to lower eye pressure. If drops are not enough, surgery may be needed. The type of surgery depends on how advanced the glaucoma is and how much vision has already been lost.\n\nSome glaucoma surgeries, including trabeculectomy, PreserFlo MicroShunt, and XEN Stent, create a new pathway for fluid to drain out of the eye. This helps lower pressure inside the eye.\n\nHowever, after surgery, the body's natural healing process can sometimes cause inflammation and scarring, which may block the new drainage pathway. If this happens, eye pressure can rise again, and the surgery may not work as well as hoped.\n\nThis study is testing whether covering the PreserFlo or XEN devices with amniotic membrane (a safe tissue already used in other eye surgeries) can reduce scarring, improve healing, and lead to better long-term results. Amniotic membrane has already been used safely in many types of eye surgeries. It has been shown to improve healing and reduce scarring in some glaucoma surgeries. But it has not yet been studied in PreserFlo MicroShunt or XEN Stent procedures. The goal is to see if adding amniotic membrane makes the surgery safer and more effective for people with glaucoma.",[555],"Glaucoma",[557,558,559,560],"Galucoma","Glaucoma Surgery","Stent surgery","MicroShunt surgery","2025-08-20",{"date":563,"type":39},"2025-08-27",{"date":565,"type":22},"2025-12-01",{"date":567,"type":22},"2027-12-31",{"name":45,"class":46},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":583,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":47},"100546070","midline-versus-dorsolateral-spinal-cord-stimulation-for-post-surgical-neuropathic-pain-100546070","NCT06390150","Midline Versus Dorsolateral Spinal Cord Stimulation for Post-surgical Neuropathic Pain","Midline Versus Dorsolateral Spinal Cord Stimulation for Post-surgical Neuropathic Pain (MIDL-SCS Trial)","MIDL-SCS","Inclusion criteria\n\n1. Diagnosis of neuropathic pain following a surgical procedure\n2. A minimum of 50% of pain should be limited to one body part, defined as one limb or one side of trunk.\n3. Failed conservative therapies (medication, physiotherapy)\n4. Disability more than 6 months\n\nExclusion criteria\n\n1. Previous implantation with SCS (i.e. revision surgery)\n2. Any underlying condition that would preclude an MRI\n3. Untreated psychiatric conditions or substance use disorder\n4. Existing medical conditions that would preclude from SCS (history of recurrent infections, uncontrolled cancer, etc.)\n5. Surgically treatable lesion (e.g. spinal stenosis, disc herniation)\n6. Lack of capacity (e.g. significant cognitive impairment",{"count":315,"type":22},[25],"The goal of this interventional study is to learn if dorsolateral spinal cord stimulation (DL-SCS) can treat focal post-surgical, medically refractory neuropathic pain. The main question it aims to answer is:\n\n\\- How does DL-SCS compare to traditional SCS and no treatment for treating post-surgical neuropathic pain?\n\nParticipants will be asked to\n\n* trial combinations of stimulation across blocks of weeks (randomized cross-over)\n* rate their pain after each stimulation trial",[581,582],"Pain, Postoperative","Neuropathic Pain",[584,585],"Spinal cord stimulation","Post intra-thoracic surgery pain syndrome","2025-07-30",{"date":588,"type":39},"2025-08-03",{"date":590,"type":22},"2025-09",{"date":592,"type":22},"2030-07",{"name":45,"class":46},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":23,"phases":604,"briefSummary":605,"conditions":606,"keywords":608,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":618},"100485023","engaging-mobile-prism-adaptation-treatment-at-home-100485023","NCT05595668","Engaging Mobile Prism Adaptation Treatment at Home","Feasibility and Effectiveness of a New Computerized Treatment Protocol for Spatial Neglect Post Stroke During Inpatient and Outpatient Rehabilitation","EMPATH","Inclusion Criteria:\n\n1. Have experienced a right hemisphere stroke (confirmed by a clinician)\n2. Experience mild to severe symptoms of neglect\n3. Be willing and able to consent to participate\n4. Be medically stable\n5. Have self-reported normal to corrected-to-normal vision\n6. Be able to point to targets presented on a computer screen\n7. Live within a two-hour radius of Halifax\n\nExclusion Criteria:\n\nOther existing neurological disorders (e.g., dementia, multiple sclerosis, epilepsy).",{"count":603,"type":22},80,[25],"Spatial neglect is a common disorder after stroke which leads to problems with noticing or responding to information from the left side of the body or space. This condition has been linked to reduced independence in a wide range of daily life activities including eating, dressing, and mobility. Despite its high prevalence in stroke patients, there is currently no standard of care for spatial neglect. Prism adaptation (PA) is a promising treatment, however, there are limitations to using PA in standard clinical care as it requires daily exposure for at least two weeks, yet access to equipment and supervision is limited. To solve this problem, the investigators have developed a new game-like PA treatment (Peg-the-Mole, PTM) that can be used at home without the need for daily in person therapist set-up and supervision. In this study the investigators aim to evaluate the feasibility and effectiveness of the gamified and portable PA procedure in an inpatient and home setting, with the hypothesis that the PA procedure will improve patient's neglect symptoms.",[607],"Spatial Neglect",[607,609,610,342],"Prism Adaptation","Rehabilitation","2025-07-25",{"date":586,"type":39},{"date":614,"type":39},"2023-09-15",{"date":616,"type":22},"2026-11",{"name":45,"class":46},4,{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":56,"enrollmentInfo":625,"targetDuration":4,"studyType":23,"phases":627,"briefSummary":628,"conditions":629,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":47},"100494712","evaluating-the-impact-of-including-virtual-dietary-education-within-an-electronic-irritable-bowel-syndrome-pathway-100494712","NCT05721742","Evaluating the Impact of Including Virtual Dietary Education Within an Electronic Irritable Bowel Syndrome Pathway","Inclusion Criteria:\n\n* Recurrent abdominal pain on average at least 1 day\u002F week in the last 3 months associated with two or more of the following criteria: related to defecation, or association with a change in frequency of stool or associated with a change in form (appearance) of stool\n* Willingness to change diet\n* Access to a device for accessing virtual dietary education\n\nExclusion Criteria:\n\n* New onset symptoms within past year in age 50 and above\n* Rectal bleeding\n* Inflammatory Bowel Disease\n* Unexplained recent weight loss\n* Gastrointestinal surgery with removal of gallbladder or segments of the bowel\n* Having an eating disorder",{"count":626,"type":22},76,[25],"Irritable bowel syndrome is a functional bowel disorder that affects many Canadians. The syndrome involves abdominal pain and change in frequency or form of bowel movements, and these symptoms can lead to a decreased quality of life for patients. Primary care physicians are dissatisfied with current referral processes, and patients may wait a long time to receive the correct diagnosis. Diet is known to exacerbate symptoms of IBS. In Canada, accessing dietary treatment for IBS is a challenge due to lack of resources. Some patients lack access to dietary interventions, and others are given advice that is not evidenced based. Use of eHealth technology, such as virtual education delivered by a dietician, may allow for more widespread access to dietary interventions for IBS. Virtual education can include one on one dietary education, online group-based education, and the use of apps. Currently, there is a gap in knowledge whether dietary intervention for IBS, delivered virtually by a dietician, is effective in treating IBS.",[630],"IBS - Irritable Bowel Syndrome","2025-07-08",{"date":633,"type":39},"2025-07-09",{"date":635,"type":39},"2023-05-16",{"date":637,"type":22},"2026-05",{"name":45,"class":46},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":23,"phases":647,"briefSummary":648,"conditions":649,"keywords":651,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":47},"100597826","feasibility-accuracy-and-reproducibility-of-virtual-reality-visual-field-testing-in-patients-with-glaucoma-100597826","NCT07063537","Feasibility, Accuracy, and Reproducibility of Virtual Reality Visual Field Testing in Patients With Glaucoma","Evaluation of the Accuracy and Reproducibility of Visual Field Testing Using a Virtual Reality Head-Mounted Device for Patients With Early, Moderate, and Advanced Glaucoma","Inclusion Criteria:\n\n* \\>18 years of age\n* diagnosis of primary open-angle glaucoma\n* ability to perform visual field testing\n* capacity to provide informed consent to research protocol\n\nExclusion Criteria:\n\n* diagnosis of secondary glaucoma or non-glaucomatous optic neuropathy\n* previous intraocular surgery (excluding cataract surgery and minimally invasive glaucoma surgery)\n* significant media opacity\n* pregnancy\n* seizure disorder\n* cardiac pacemaker\u002Fother implantable device\n* severe vertigo\u002Fbalance disorder",{"count":149,"type":22},[25],"The goal of this clinical trial is to evaluate the feasibility of using virtual reality based visual field testing to monitor glaucoma in a clinical setting. This will be done through comparison of a virtual reality (VR) based device to the current gold standard Ziess Humphrey Field Analyzer (HFA). The main questions the study aims to answer are:\n\n* Can both devices produce similar results in terms of detecting visual field defects and progression?\n* Does the stage (early, moderate, advanced) of glaucoma impact results between the two devices?\n\nParticipants will perform both a standard and a VR based visual field test at each visit, for a total of 5 visits.",[650],"Glaucoma Open-Angle",[532,652,555],"Visual Field","2025-07-02",{"date":655,"type":39},"2025-07-14",{"date":657,"type":39},"2024-12-14",{"date":659,"type":22},"2025-10",{"name":45,"class":46},{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":4,"eligibilityCriteria":667,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":668,"targetDuration":4,"studyType":23,"phases":670,"briefSummary":671,"conditions":672,"keywords":676,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":4},"100578598","neurocognitive-remediation-for-adults-with-osis-100578598","NCT06813378","(Neuro)Cognitive Remediation for Adults With OSIs","(Neuro)Cognitive Remediation for Adults With Operational Stress Injuries","Inclusion Criteria:\n\nParticipants must be:\n\n* Clients engaging in treatment at the Nova Scotia OSI Clinic who may benefit from the CR program.\n* Be experiencing cognitive challenges which may be improved through the cognitive remediation program, as determined by the treating Occupational Therapist.\n\nExclusion Criteria:\n\nParticipants must not:\n\n-Be accessing CR treatment modality through an Occupational Therapist",{"count":669,"type":22},20,[25],"(Neuro)Cognitive remediation (CR) is an intervention for people experiencing cognitive impairments that interfere with their daily functioning. Cognition refers to a person's ability to perceive, process, manipulate and respond to information. Attention, memory, abstract reasoning, and processing speed are all examples of cognitive skills. By focusing on improving these underlying skills, the overall aim of cognitive remediation is to improve the participant's daily satisfaction and success. CR can be achieved through teaching compensatory strategies, restoration of cognition through drill and practice and by utilizing regulative metacognitive strategies. Acquired skills and strategies are then 'bridged' or applied to daily functioning with the assistance of the clinician.\n\nThis pilot study intends to assess the impacts of a CR program on a population of Military Veterans, police officers, and retirees within the Nova Scotia Operational Stress Injury Clinic (NSOSIC). Researchers believe this program will improve cognitive functioning and that participants will perceive that the program was beneficial.",[673,674,675],"PTSD","Cognitive Impairment","Cognitive Dysfunction",[673,677,678,679],"Military","Veteran","Cognitive Remediation","2025-06-05",{"date":682,"type":39},"2025-06-08",{"date":684,"type":22},"2025-08",{"date":686,"type":22},"2026-12",{"name":45,"class":46},""]